ArticleClinical and translational allergy2026
A Real-World Cross-Sectional Study on Suspected Mast Cell Activation Syndrome: Multiple Heterogeneous Symptoms Identified.
Article in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA variety of clinical signs and symptoms have been described in patients suspected of having mast cell activation syndrome (MCAS), however, symptom patterns and linked organ systems were not yet described.
methodsThis cross-sectional online survey included adults with physician-diagnosed self-assessed or suspected MCAS between June and September 2021. Symptoms were collected as free-text responses, and coded using the Medical Dictionary for Regulatory Activities (MedDRA). These data were then analyzed using an unsupervised machine learning approach to identify distinct participant clusters. Patient-reported outcome measures (PROMs), including the PHQ-2, GAD-7, and SF-36, were used to assess mental health symptoms and health-related quality of life.
resultsA total of 592 patients (mean age 45 years, 90% female) reported 400 symptoms in 58 categories. The hierarchical clustering algorithm failed to identify distinct patient clusters. We identified 256 (43%) patients with signs and symptoms aligning with the diagnostic criteria for MCAS including the most prevalent symptoms. Overall, patients infrequently reported mast cell-mediated skin symptoms, such as pruritus (13%), wheals (9%), flushing (7%), or angioedema (1%). We identified patients with comorbid signs of depression (39%), general anxiety (34%), and impaired quality of life (28%).
conclusionPatients with suspicion of MCAS exhibit highly heterogeneous symptoms, whereas almost 50% report symptoms corresponding to the first diagnostic criterion for MCAS. Because over a third of the patients were tested positive for other diseases, we recommend considering common and more treatable diagnoses when evaluating patients with suspected MCAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.